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Utilizing multiple tracking techniques, track the velocity, strain and stain rate of ca-
rotid. The mechanical parameters which were used for statistical analysis at different
points of carotid intima were measured simultaneously and calculated automatically at
different time of before and after treatment of rosuvastatin for 6 months were
compared and studied.
Results: The level of IMT after treatment of rosuvastatin was lower than that before
treatment (P<0.05), the systolic maximum velocity and strain rate after treatment of
rosuvastatin in carotid atherosclerosis plaque were lower signiﬁcantly than those
before treatment of rosuvastatin (all P<0.01).
Conclusions: MTT technique could early quantitatively evaluate the effect of rosu-
vastatin on the elasticity degree of blood vessel wall, artherosclerosis and the mech-
anism asynchrony of the plaque intima. So, rosuvastatin therapy in Patients with
Metabolic Syndrome could not only effectively prevent artherosclerosis, but also
reduce the damage of target organ at the same time, which have a signiﬁcant effect to
early protect the cardiovascular system.GW25-e0441
Impact of endogenous oestrogens on the risk of no-reﬂow in postmenopausal
women with ST-elevation acute myocardial infarction
Dong Mei, Yang Jun
Yantai Yuhuangding Hospital
Objectives: There is evidence that sex hormones, particularly estrogens, regulate
inﬂammation, a process integral to myocardial no-reﬂow. Thus, we prospectively
assessed the effects of endogenous estrogen on the risk of myocardial no-reﬂow in
postmenopausal women with ST-elevation myocardial infarction (STEMI).
Methods: Consecutive 100 postmenopausal women, diagnosed with STEMI and
undergoing emergence percutaneous coronary intervention (PCI) were included in
this study. Blood samples were obtained before PCI and assayed for endogenous
sex hormones. Logistic regression models were developed with adjustment for
confounders.
Results: Compared with normal reﬂow group, the circulating levels of estrone,
estradiol, sex hormone binding globulin (SHBG) and Hypersensitive C-reaction
protein (Hs-CRP) were signiﬁcantly higher in no-reﬂow group (P<0.05). The per-
centage of diabetes mellitus was higher in the no-reﬂow group compared with normal
reﬂow group (47.8% versus 24.7%, respectively; P¼0.034). In univariable logistic
regression models, diabetes mellitus, lesion length, reference luminal diameter,
thrombus score4 and the levels of estrone, estradiol and SHBG were all found to be
positively associated with the risk of no-reﬂow (P<0.05). After adjusting for these
factors, diabetes mellitus (OR¼9.764, CI 4.888-192.631; P¼0.025), thrombus
score4 (OR¼5.547, CI2.247-12.510; P¼0.042) and estradiol levels (OR 4.647, CI
1.148-10.238; P¼0.043) continued to demonstrate strong positive associations with
the risk of no-reﬂow.
Conclusions: Our data showed that high circulating levels of endogenous estrogens
have a positive and statistically signiﬁcant relationship with no-reﬂow in post-
menopausal women with STEMI. It suggested that estrogens had a potential detri-
mental effect on myocardial no-reﬂow.GW25-e1555
The Risk Factors of Malignant Ventricular Arrhythmia in the early stages of
elderly Patients with Acute Myocardial Infarction
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Objectives: To invetigate the incidence, mortality and risk factors of malignant
ventricular arrhythmia in the early stages of elderly patients with acute myocardial
infarction.
Methods: A retrospecttive study was conducted on 420 elderly patients with acute
myocardial infarction from January 2009 to June 2013. According to the Holter
outcomes, the patients were divided into two groups, malignant ventricular arrhythmia
(MVA) group and non-MAV group. Gender, age, history of diabetes, hypertension,
hyperlipidemia, old myocardial infarction and smoking, count of white blood cell,
hemoglobin, neutrophil, platelet, total cholesterol, low density lipoprotein, high
density lipoprotein, triglycerides, potassium, blood urea nitrogen, serum creatinine,
blood glucose, creatine kinase, creatine kinase MB, Troponin I, Killip class, corrected
Tpeak-Tend interval, heart rate variability, opening of infarct-related artery by direct
PCI, ultrasound results were recorded. Then the related factors were compared be-
tween the two groups and logistic regression analysis was applied to determine the risk
factors for MAV.
Results: Among the 420 patients, MVA occurred in 152 patients and 26 patients died
of MVA. Logistic regression analysis showed that advanced age, elevated creatine
kinase-MB and Troponin I, low blood potassium, higher Killip class of cardiac
function, reduced heart rate variability, not opening of infarct-related artery by direct
PCI, reduced LVEF were risk factors of MVA.
Conclusions: The incidence and mortality of MVA in elderly patients with acute
myocardial infarction was higher, more clinical attention should be paid to the elderly
patients who have the above risk factors.C132 JACC Vol 64/16/Suppl C j October 16–1GW25-e0235
Effects of Liraglutide on Glycemic Control and Left Ventricular Function in
Patients with Acute Myocardial Infarction: a Randomized, Double-blind,
Placebo-controlled Clinical Trial
Chen Weiren, Yun-Dai Chen
PLA General Hospital at Beijing, China
Objectives: Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates
plasma glucose, and GLP-1 analogues were recently introduced for the treatment of
acute myocardial infarction (AMI).We planned to evaluate the effects of liraglutide on
left ventricular function in patients with AMI.
Methods: A total of 62 patients with AMI were enrolled in this study between
October 2013 and January 2014. Of these, 50 patients were randomized 1:1 to receive
either liraglutide or placebo for 7 days.
Results: At 7 days, the primary end point, the difference in the change in left ven-
tricular ejection fraction between the two groups was +5.5% (liraglutide vs. placebo
95% CI +1.3% to +11.2% P < 0.001). After 7 days of treatment, the fasting glucose
levels decreased signiﬁcantly greater in the liraglutide group (4.0  2.4 mmol/L),
compared with that in the control group (2.5  1.9 mmol/L, vs. liraglutide group
P¼0.01). The difference in decrease in serum high sensitivity C reactive protein levels
was 0.22 mg/dL (liraglutide vs. placebo 95% CI 0.42 to 0.02; P ¼ 0.002). The dif-
ference in rise in serum superoxide dismutase levels after 7 days of treatment was
+14.9 U/mL (liraglutide vs. placebo 95% CI +3.1 to +26.1; P < 0.001).
Conclusions: GLP1 could improve glucose metabolism and left ventricular function
in patients with AMI, making it a potential adjuvant therapy for AMI.
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Effect of different doses of rosuvastatin on serum concentrations of VCAM-1,
ICAM-1 and PAI-1 in the patients with acute coronary syndrome
Zhang Li-Zhen, Ma Xiu-Rui, Zhang Zhun-Lin, Zhu Li-Jun, Chen Jie
Shanxi Cardiovascular Hospital
Objectives: To explorer the effect of different doses of rosuvastatin on serum con-
centrations of vascular cell adhesion molecule-l (VCAM-1), intercellular adhesion
molecule-l (ICAM-1), plasminogen activator inhibitor-1 (PAI-1) in the patients with
acute coronary syndrome (ACS).
Methods: A total of 236 patients with acute coronary syndrome were randomly
divided into A group (128 patients were administrated to rosuvastain 10mg per day)
and B group (128 patients were administrated to rosuvastain 20mg per day). Another
50 agedmatched healthy subjects who were conﬁrmed no coronary artery stenosis by
coronary angiography were enrolled as control group.Serum samples of the patients in
both A and B group were collected in order to detect the level of VCAM-1, ICAM-1,
PAI-1 before the patients accept the treatment of rosuvastain. Moreover the serum
levels of VCAM-1, ICAM-1 and PAI-1 were measured 1 and 2 weeks after rosu-
vastain treatment by Enzyme Linked Immunosorbent Assay (ELISA).
Results: Compared with the control group, signiﬁcantly increasing of the serum
concentration of VCAM-1 (706.653.6ug/L vs. 56047.2ug/L, P<0.05), ICAM-1
(375.334.6ug/L vs. 27635.2ug/L, P<0.05) and PAI-1 (55.47.9ng/L vs.
42.38.1ng/L, P<0.05) were observed in patients with ACS. The serum levels of
VCAM-1, ICAM-1 and PAI-1 signiﬁcantly decreased from 711.554.6 to
623.758.9ug/L (p <0.05), 389.523.7 to 352.630.5ug/L (p <0.05) and 57.68.2
to 50.29.3ng/L (p <0.05) in the A group 1 week after the treatment of rosuvastain
and from 699.162.8 to 603.260.7 ug/L (p <0.05), 370.442.3 to 337.628.3 ug/L
(p<0.05) and 53.46.9 to 46.58.8 ng/L (p <0.05) in the B group 1 week after the
treatment of rosuvastain, respectively. 2 weeks after the treatment of rosuvastain, the
serum concentration of VCAM-1, ICAM-1, PAI-1 were decreased both in A and B
group (P<0.05). Whereas in the B group, the serum concentration of VCAM-1,
ICAM-1, PAI-1 were lower than that in the A group 2 weeks after the treatment of
rosuvastatin 51237.4 vs. 55642.2 ug/L (P<0.05), 24638.4 vs. 27134.6ug/L
and 38.68.3 vs. 43.87.6 ng/L (P<0.05), respectively.
Conclusions: Signiﬁcant decreases of VCAM-1, ICAM-1 and PAI-1 in the sera of
ACS patients were observed at both 1 and 2 weeks after treatment with rosuvastatin,
and signiﬁcantly greater reduction were observed with the dose of rosuvastatin
increasing.
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Association between the QRS complex duration on admission and the prognosis
of in-patient in people who suffered acute myocardial infarction
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Objectives: To investigate the association between the QRS complex duration
(QRSd) on admission and the prognosis of in-patient in people who suffered acute
myocardial infarction.
Methods: In retrospective method, enroll patients of cardiovascular department of the
ﬁrst hospital attached to Jilin university from 01/01/2002 to 01/01/2008. All patients
suffered from acute ST segment elevation myocardial infarction (STEMI) and
excluded the following situations: 1) established stroke history; 2) completely atrial
ventricular block; 3) intraventricular aberrant conduction and other clinical situations9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
